Association of GLP-1 receptor agonist and SGLT2 inhibitor use with outcomes in patients with type 2 diabetes undergoing pacemaker implantation.
AIMS Heart failure (HF) remains prevalent following pacemaker implantation, with patients with type 2 diabetes mellitus (T2DM) representing a particularly vulnerable population. Whether use of contemporary glucose-lowering therapies is associated with subsequent clinical outcomes has not been well characterized. We inv...